The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.

A memristive/memcapacitive device with vertex double-helical polarized biomimetic protein nanotubules forming double membranes with potential gradient mimicking mitochondria's inner double membrane was invented. The memristive/memcapacitive device comprises a cross-linked conductive organic polymer having a single-wall cross-bar polarized nanotube self-assembling membrane (SAM) on a gold chip with a minimum 5 nm space between the nanotubes. Under an applied potential, a pair of vertex double-helical circular current flow induced the Fermi arcs states promoting a direct chelating with zinc ions of the Matrix Metalloproteinase (MMP-2), that made a dual-functioning direct ultrasensitive detection of protein in an attomolar concentration possible without a procedure of cycteine switch under label-free, probe-free and reagent-free conditions. The energy harvesting feature is also disclosed.

Compositions and methods are provided that improve detection of botulinum neurotoxins in cell-based assays. In one aspect an isoquinolynyl compound can be used to enhance the sensitivity of both Frster resonance energy transfer (FRET) and non-FRET cell-based assays. Osmolarity of the cell culture media can be adjusted to optimize the effect of the compound. In that subject matter an environment cell can include an enzyme that facilitates degradation of the reporter significantly faster after the cleavage than before the cleavage, and presence of the Botulinum toxin correlates with reduction of the signal from a baseline signal. Where the environment is a cell, the cell can advantageously express both the construct that includes the reporter, and an enzyme that facilitates the degradation.

Methods for quantifying the amount of drug present in a prodrug composition are provided.

The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.

The present disclosure provides anti-SAS1B antibodies, antigen-binding fragments thereof, and antibody-drug conjugates and methods of their use. This present disclosure also provides an isolated antibody or antigen-binding portion thereof having at least one of SB antibodies binding to surface exposed SAS1B, and 6B1 antibodies identifying at least one set of cancer patients testing positive for SAS1B expression.

The present invention refers to an In vitro method for screening for subjects at risk of developing thoracic aortic aneurysm (TAA) or a disease causing TAA comprising: (a) measuring the expression pattern or level of at least A Disintegrin And Metalloproteinase with Thrombospondin Motifs 1 (ADAMTS1) obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least ADAMTS1 of the subjects to be screened with an already established expression pattern or level, wherein reduced expression of at least ADAMTS1 is indicative of a thoracic aortic aneurysm (TAA).

Described herein is an enzyme detection device for use in the detection of enzyme activity in a test sample. Also provided are indicator molecules for use in the detection of enzyme activity, particularly enzyme cleavage activity, in a test sample, and to methods for detecting the presence of enzyme activity.

The present invention generally pertains to methods of characterizing of a protein of interest. In particular, the present invention pertains to the use of post-column denaturation, size exclusion chromatography and mass spectrometry for detecting, identifying and characterizing crosslinking amino acid residues in a therapeutic antibody.

The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.